Benefits of SGLT2i in heart failure across a broad range of ejection fractions: new opportunities and future challenges
- PMID: 36370027
- DOI: 10.1093/eurheartj/ehac649
Benefits of SGLT2i in heart failure across a broad range of ejection fractions: new opportunities and future challenges
Conflict of interest statement
Conflict of interest: M.V. reports personal fees for speaker bureau and/or consulting in Advisory Board from Amarin, Amgen, Astra Zeneca, Kalos Medical, Menarini Int, Novartis Pharma, Novo Nordisk, outside the submitted work. C.P. reports personal fees from Acticor Biotech, personal fees from Amgen, personal fees from Bayer, personal fees from GlaxoSmithKline, personal fees from Tremeau, personal fees from Zambon, grants from AIFA (Italian Drug Agency), grants from European Commission, other from Scientific Advisory Board of the International Aspirin Foundation, outside the submitted work.
Comment on
-
SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials.Lancet. 2022 Sep 3;400(10354):757-767. doi: 10.1016/S0140-6736(22)01429-5. Epub 2022 Aug 27. Lancet. 2022. PMID: 36041474
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
